Home HOMEPAGE   Fri, 12/06/2024 GMT + 7
    Q & A   Site map Forum   Site map Sitemap   E-mali Contact   Vietnamese Vietnamese
IMPE-QN
Web Sites & Commerce News - Events
Web Sites & Commerce Introduction
Web Sites & Commerce Collaborative activities
Web Sites & Commerce Training
Web Sites & Commerce Specific research studies
Web Sites & Commerce Publications
Web Sites & Commerce Mass organization activities
Web Sites & Commerce Legal documents
Web Sites & Commerce Statistical data
Web Sites & Commerce Work safety
Web Sites & Commerce Vietnam`s Physicians
Finance & Retail Malariology
Epidemiology
Malaria parasitology
Entomology
Diagnosis and Treament
Antimalarial drugs and drug resistant parasites
Malaria Vaccines
Health education and communication
Molecular - biology
Web Sites & Commerce Helminthology
Web Sites & Commerce Other vector-borne diseases

SEARCH

LOGIN
Username
Password

WEBLINKS
Other links

Visiting users: 491
5 4 6 1 9 3 3 7
Online
4 9 1
 Malariology Malaria Vaccines
While the vaccine candidate did not prevent malaria infection, it did significantly delay parasitemia in 59 per cent of vaccinated subjects. (Source: Thinkstock Images)
New malaria vaccine generates robust immune response

The vaccine candidate is the first in-human study of its kind under an investigational new drug application with the US FDA.

A new malaria vaccine candidate has been found to generate robust immune response while significantly delaying arasitemia in 59 per cent of vaccinated subjects, according to a first-of-its-kind in-human study.

Plasmodium vivax malaria is challenging to control because it can be dormant, causing no symptoms, and then become active causing symptomatic malaria weeks to months after initial infection. The vaccine candidate, developed by researchers at Walter Reed Army Institute of Research (WRAIR) in the US and tested jointly with GlaxoSmithKline (GSK) to prevent vivax malaria infection, is the first in-human study of its kind under an investigational new drug application with the US Food and Drug Administration.

WRAIR researchers immunised 30 volunteers with three doses of the vaccine candidate. Immunised volunteers took part in WRAIR?s well-established controlled human malaria infection (CHMI) model where they were bitten by malaria-infected mosquitoes. The efficacy of the vaccine candidate was then determined based o­n whether or not volunteers developed malaria by looking at blood smears or if it took longer for malaria parasites to appear in the blood.

"This study represents the first vaccine study to test the effectiveness of a P vivax vaccine candidate in humans using controlled human malaria infection," said Jason W Bennett, the study's lead investigator. Unlike P falciparum where a CHMI model is well established, the P vivax CHMI model must rely o­n blood donations from infected humans to initiate infections in mosquitoes. The vaccine candidate was well tolerated in all volunteers and generated robust immune responses. While the vaccine candidate did not prevent malaria infection, it did significantly delay parasitemia in 59 per cent of vaccinated subjects.

Parasitemia is used as a measurement of parasite load in the organism and an indication of the degree of an active parasitic infection. Robert Paris, director of the US Military Malaria Research Programme at WRAIR, said that an improved vaccine can be designed. "Findings from the analysis of the immune response of vaccinated subjects have given us clues to improve vaccine candidates and studies are now underway at WRAIR to develop next generation vivax vaccines," said Paris.

Researchers were also able to demonstrate that individuals with low or absent levels of a specific liver enzyme were unable to convert primaquine, the o­nly FDA-approved drug to treat the dormant stages of vivax malaria, to an active drug form to kill the dormant stage of the parasites. The findings were published in the journal PLOS Neglected Tropical Diseases.

03/02/2016
(Source: indianexpress.com)  

Announcement

LIBRARY
Book
Magazine
Document
Photos
Thesis
Documentary form
Research studies
PROFFESSIONAL SOFTWARE
Malaria forecast & management
Document management
Personel management
LEGAL DOCUMENTS
Law
Decision
Decree
Instruction
Circular
Official document
Reports
Others
SPECIFIED IMFORMATION
Malaria facts
Malaria epidemic
Petechial fever
HEALTH SERVICES
Hospital & medical centre
Drugstore
Surgery
Your doctor

Institue of Malariology Parastology and Entomology Quy Nhon
Address: 611B Nguyen Thai Hoc Str,. Quy Nhon City
Tel: (84) 056 846571 Fax: (84) 056 846755
• Designed by Quang Ich JSC